117 related articles for article (PubMed ID: 15645138)
21. Interaction proteomics of the HMGA chromatin architectural factors.
Sgarra R; Furlan C; Zammitti S; Lo Sardo A; Maurizio E; Di Bernardo J; Giancotti V; Manfioletti G
Proteomics; 2008 Nov; 8(22):4721-32. PubMed ID: 18850631
[TBL] [Abstract][Full Text] [Related]
22. HMGA2 expression in a canine model of prostate cancer.
Winkler S; Murua Escobar H; Meyer B; Simon D; Eberle N; Baumgartner W; Loeschke S; Nolte I; Bullerdiek J
Cancer Genet Cytogenet; 2007 Sep; 177(2):98-102. PubMed ID: 17854662
[TBL] [Abstract][Full Text] [Related]
23. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
Wang JC; Bégin LR; Bérubé NG; Chevalier S; Aprikian AG; Gourdeau H; Chevrette M
Clin Cancer Res; 2007 Apr; 13(8):2354-61. PubMed ID: 17406028
[TBL] [Abstract][Full Text] [Related]
24. High Mobility Group A (HMGA) proteins: Molecular instigators of breast cancer onset and progression.
Sgarra R; Pegoraro S; Ros G; Penzo C; Chiefari E; Foti D; Brunetti A; Manfioletti G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):216-229. PubMed ID: 29518471
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
26. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
27. Identification of new high mobility group A1 associated proteins.
Pierantoni GM; Esposito F; Giraud S; Bienvenut WV; Diaz JJ; Fusco A
Proteomics; 2007 Oct; 7(20):3735-42. PubMed ID: 17880001
[TBL] [Abstract][Full Text] [Related]
28. The HMGA proteins: a myriad of functions (Review).
Cleynen I; Van de Ven WJ
Int J Oncol; 2008 Feb; 32(2):289-305. PubMed ID: 18202751
[TBL] [Abstract][Full Text] [Related]
29. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
30. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
[TBL] [Abstract][Full Text] [Related]
31. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer.
Sgarra R; Rustighi A; Tessari MA; Di Bernardo J; Altamura S; Fusco A; Manfioletti G; Giancotti V
FEBS Lett; 2004 Sep; 574(1-3):1-8. PubMed ID: 15358530
[TBL] [Abstract][Full Text] [Related]
32. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death.
Baldassarre G; Belletti B; Battista S; Nicoloso MS; Pentimalli F; Fedele M; Croce CM; Fusco A
Oncogene; 2005 Oct; 24(45):6809-19. PubMed ID: 16007157
[TBL] [Abstract][Full Text] [Related]
33. Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer.
Wang J; Thompson B; Ren C; Ittmann M; Kwabi-Addo B
Prostate; 2006 May; 66(6):613-24. PubMed ID: 16388505
[TBL] [Abstract][Full Text] [Related]
34. PrLZ is expressed in normal prostate development and in human prostate cancer progression.
Wang R; Xu J; Mabjeesh N; Zhu G; Zhou J; Amin M; He D; Marshall FF; Zhau HE; Chung LW
Clin Cancer Res; 2007 Oct; 13(20):6040-8. PubMed ID: 17947466
[TBL] [Abstract][Full Text] [Related]
35. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
36. Vasoactive intestinal peptide induces cyclooxygenase-2 expression through nuclear factor-kappaB in human prostate cell lines Differential time-dependent responses in cancer progression.
Fernández-Martínez AB; Collado B; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ
Mol Cell Endocrinol; 2007 May; 270(1-2):8-16. PubMed ID: 17434257
[TBL] [Abstract][Full Text] [Related]
37. Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer.
Horvath LG; Lelliott JE; Kench JG; Lee CS; Williams ED; Saunders DN; Grygiel JJ; Sutherland RL; Henshall SM
Prostate; 2007 Jul; 67(10):1081-90. PubMed ID: 17476687
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the RSL1-dependent conditional expression system in LNCaP prostate cancer cells and development of a single vector format.
Lessard J; Aicha SB; Fournier A; Calvo E; Lavergne E; Pelletier M; Labrie C
Prostate; 2007 Jun; 67(8):808-19. PubMed ID: 17373718
[TBL] [Abstract][Full Text] [Related]
39. Acetylation and phosphorylation of high-mobility group A1 proteins in PC-3 human tumor cells.
Jiang X; Wang Y
Biochemistry; 2006 Jun; 45(23):7194-201. PubMed ID: 16752910
[TBL] [Abstract][Full Text] [Related]
40. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP.
Koochekpour S; Lee TJ; Wang R; Sun Y; Delorme N; Hiraiwa M; Grabowski GA; Culig Z; Minokadeh A
J Cell Biochem; 2007 Jun; 101(3):631-41. PubMed ID: 17171640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
